What sector does SANTEN PHARMACEUTICAL CO.,LTD. belong to?

SANTEN PHARMACEUTICAL CO.,LTD. operates in the Pharmaceuticals sector, specifically the Pharmaceutical industry, and is listed on the US markets.

What is the current share price of 4536?

As of the latest available quote, 4536 traded at ¥1,725.00. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of 4536?

SANTEN PHARMACEUTICAL CO.,LTD. has a price-to-earnings (P/E) ratio of about 15.15. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of 4536?

The market capitalisation of SANTEN PHARMACEUTICAL CO.,LTD. is approximately ¥565.25B.

Is SANTEN PHARMACEUTICAL CO.,LTD. profitable?

For its latest reported financial year, SANTEN PHARMACEUTICAL CO.,LTD. recorded a net profit margin of about 12.81%.

Does 4536 pay a dividend?

SANTEN PHARMACEUTICAL CO.,LTD. currently has a dividend yield of about 2.18%.

What is the return on equity (ROE) of 4536?

SANTEN PHARMACEUTICAL CO.,LTD. has a return on equity (ROE) of about 12.80%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of 4536?

Over the past 52 weeks, 4536 has traded between a low of ¥1,458.00 and a high of ¥2,254.00.

SANTEN PHARMACEUTICAL CO.,LTD.

4536 TSE Pharmaceuticals Pharmaceutical

TSE Prime

¥1,725.00

-1.15%

Delayed · cached 15 min

Fair value analysis

4536

SANTEN PHARMACEUTICAL CO.,LTD.

¥1,725.00

Close used for this calculation

¥1,949.85Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

63/100

Profitability15/25

Returns13/25

Balance Sheet21/25

Efficiency14/25

Growth11/25

Good

Quality radar

Consensus fair value

¥1,949.85

Near FV

▲ +13.0% against the close used

Model range ¥671.05 – ¥2,694.49

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear¥671.05Fair value¥1,949.85Bull¥2,694.49

FairClose

52-week traded range

52W low ¥1,467.5052W high ¥2,236.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

SANTEN PHARMACEUTICAL CO.,LTD. closed at ¥1,725.00, 11.5% below the consensus fair value of ¥1,949.85 drawn from 9 valuation models.

Financial DNA score 63/100 — Good. P/E of 15.1x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

¥2,126.92

+23.3%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=8.3%, r=10%, tg=3%, n=10yr

Graham Number

¥1,006.41

-41.7%

√(22.5 × EPS × BVPS)

EPS=114.04, BVPS=394.74 · outside Graham range (P/E 15.1, P/B 4.4) — asset-light, treat as a rough floor

P/E Fair Value

¥2,280.80

+32.2%

EPS × 20x (sector P/E)

EPS=114.04, Sector P/E=20x

Peter Lynch (PEG)

¥940.83

-45.5%

EPS × Growth% (PEG = 1 is fair)

EPS=114.04, g=8.3%

EV/EBITDA

¥2,694.49

+56.2%

(EBITDA × 14.1x − Net Debt) ÷ Shares

EBITDA=66.16B

Dividend Discount (DDM)

¥2,049.30

+18.8%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=37.95, r=10%, g=8%

Book Value (P/B)

¥671.05

-61.1%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=394.74, ROE=12.8%, g=6%, r=10%

Reverse DCF

¥1,725.00

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 3.4% | Historical: 8.3%

Margin of Safety

¥1,353.53

-21.5%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=1804.71, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer